Tulkens et al. 2009. Torezolid (TR-700), a Novel Methyltetrazolyl-oxazolidinone, Accumulates Markedly within Human THP-1 Macrophages and Shows Activity towards Intraphagocytic Legionella pneumophila: Comparison with Linezolid. Posters of the 49th ICAAC (C1-1934).

Brown-Driver et al. 2008. In Vitro and in Vivo Efficacy of TR-701 and TR-700 versus the Linezolid-and Methicillin-Resistant Staphylococcus aureus cfr Strain CM/05. Posters of the 48th ICAAC (F-2065).

Lemaire et al. 2009. Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines. J Antimicrob Chemother. 64: 1035-1043

Chambers et al. 2009. Comparative Efficacy of TR-701, Vancomycin (Vanco), and Daptomycin (Dapto) in a Rabbit Model of Methicillin-Resistant Staphylococcus aureus (MRSA) Endocarditis. Posters of the 49th ICAAC (B-050).

Choi et al. 2007. In Vitro and in Vivo Antibacterial Activity of TR-701 (DA-7218) against Penicillin-Resistant Streptococcus pneumoniae. Posters of the 47th ICAAC (F-1689).

Choi et al. 2007. TR-701 (DA-7218) is Significantly More Potent than Linezolid in Skin and Soft Tissue Models of Infection. Posters of the 47th ICAAC (F-1691).

Jones et al. 2008. TR-700, a Novel Oxazolidinone, Tested Against Linezolid-Resistant Gram-positive Species with Well-Characterized Resistance Mechanisms. Posters of the 48th ICAAC (F-2061).

Schaadt et al. 2009. The in Vitro Activity of TR-700, the Active Ingredient of the Antibacterial Prodrug TR-701, a Novel Oxazolidinone Antibacterial Agent. Antimicrob Agents Chemother. 53: 3236:3239.
Poster F1-1687.

Morales et al. 2009. Activity of Torezolid (TR-700) Against Linezolid-resistant MRSA Strains with cfr gene Mediated Resistance. Posters of the 49th ICAAC (E-808).

Locke et al. 2009. Novel Ribosomal Mutations in Staphylococcus aureus Identified Through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700). Antimicrob Agents Chemother. 53(12): 5265-5274.
Poster ECCMID 2009.

Locke et al. 2009. Mutations in Ribosomal Protein L3 are Associated with Oxazolidinone Resistance in Staphylococci of Clinical Origin. Antimicrob Agents Chemother. 53(12): 5275-5278.
Poster C1-1349 2009.

Locke et al. 2009. Genetic Environment and Instability of Cfr in MRSA CM05. Posters of the 49th ICAAC (C1-1364b).

Shaw et al. 2008. In vitro Activity of TR-700, the Antibacterial Moiety of the Prodrug TR-701, Against Linezolid-resistant Strains. Antimicrob Agents Chemother. 52:4442-7.
Poster F1-1688.

Betriu et al. 2009. Comparative Activity of TR-700 Against Staphylococci Blood Isolates Collected in Spain. Posters of the 49th ICAAC (E-807).

Prokocimer et al. 2009. Safety and Efficacy of TR-701 in a Phase 2 Randomized, Double-Blind Study in Patients with Severe Complicated Skin and Skin Structure Infections (cSSSI). Posters of the 49th ICAAC (L1-335).

Prokocimer et al. 2008. Human Pharmacokinetics of the Prodrug TR-701 and TR-700, its Active Moiety, after Multiple Oral Doses of 200 and 400 mg TR-701, a Novel Oxazolidinone. Posters of the 48th ICAAC (F1-2064).

Prokocimer et al. 2009. The Safety of Single Ascending Oral Doses of TR-701, a Novel Oxazolidinone Prodrug Antibiotic. Posters of the 19th ECCMID (P-1090).

Bien et al. 2008. Human Pharmacokinetics of TR-700 after Ascending Single Oral Doses of the Prodrug TR-701, a Novel Oxazolidinone Antibiotic. Posters of the 48th ICAAC (F1-2063).

Munoz et al. 2009. Effect of Food on the Pharmacokinetics of TR-701, a Novel Oxazolidinone Antibiotic Prodrug, in Healthy Adult Subjects. Posters of the 19th ECCMID (P-1091).

Nonclinical Studies

Schlosser et al. 2008. Absence of a Pressor Response to Oral Tyramine in Conscious Telemetrized Rats Treated with the Novel Oxazolidinone TR-701: Comparison to Linezolid. Posters of the 48th ICAAC (F1-2067).

Choi et al. 2007. Single and Repeated-Dose Toxicity of TR-701 (DA-7218) in Rodents. Posters of the 47th ICAAC (F1-1693).